タンパク質工学市場-世界の産業規模、シェア、動向、機会、予測、2018～2028年、製品タイプ、技術、エンドユーザー、地域別、競合

世界のタンパク質工学市場は、2022年に25億6,000万米ドルと評価され、2028年までのCAGRは11%で、予測期間中に目覚ましい成長を遂げると予測されています。

タンパク質工学はバイオテクノロジーの一分野であり、タンパク質を意図的に設計、修正、最適化することで、新しい機能を生み出したり、既存の機能を改善したり、特定の用途向けに調整したりします。タンパク質は、化学反応の触媒（酵素）、分子の輸送、構造的支持の提供、細胞プロセスの制御など、生体内で幅広い機能を果たす不可欠な生体高分子です。タンパク質工学は、タンパク質の構造と機能を理解することで、これらの分子を様々な目的のために操作するものです。分子生物学技術の進歩により、特定の配列を持つタンパク質をコードする遺伝子の合成や改変が可能になっています。これにより、研究者はまったく新しいタンパク質を作ったり、既存のタンパク質をさまざまな用途向けに改変したりできるようになっています。

モノクローナル抗体、ワクチン、その他のタンパク質ベースの治療法を含むバイオ医薬品に対する需要の高まりは、重要な原動力となっています。タンパク質工学技術は、これらの医薬品の生産と効能を最適化するために不可欠です。ゲノミクス、トランスクリプトミクス、プロテオミクスの継続的な進歩は、疾患経路におけるタンパク質の役割に関する貴重な洞察をもたらしています。この知識は、標的療法を開発するためのタンパク質工学技術の需要を煽っています。バイオテクノロジー業界と製薬業界は持続的な成長を遂げており、研究開発への投資も増加していました。この成長により、タンパク質工学ツールやサービスの需要が高まっていました。タンパク質工学は、希少疾患や希少疾病の治療法開発において重要な役割を果たしていました。このニッチ市場で高いリターンが期待できることが、投資と技術革新の原動力となっています。タンパク質工学は、バイオ燃料生産、食品加工、廃棄物管理など、さまざまな産業用途向けに特性を強化した酵素の設計に利用されています。

主要市場促進要因

技術の進歩

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界のタンパク質工学市場展望

• 市場規模と予測
  • 金額別
• 市場シェアと予測
  • 製品タイプ別（インスリン、モノクローナル抗体、凝固因子（血液因子＋組織プラスミノーゲン）、ワクチン、成長因子（ホルモン＋サイトカイン）、その他の製品タイプ）
  • 技術別（非合理的タンパク質設計、合理的タンパク質設計）
  • エンドユーザー別（製薬・バイオテクノロジー企業、学術機関、CRO（医薬品開発業務受託機関））
  • 地域別
  • 企業別（2022年）
• 市場マップ

第6章 アジア太平洋のタンパク質工学市場展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • 製品タイプ別
  • 技術別
  • エンドユーザー別
  • 国別
• アジア太平洋：国別分析
  • 中国
  • インド
  • オーストラリア
  • 日本
  • 韓国

第7章 欧州のタンパク質工学市場展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • 製品タイプ別
  • 技術別
  • エンドユーザー別
  • 国別
• 欧州：国別分析
  • フランス
  • ドイツ
  • スペイン
  • イタリア
  • 英国

第8章 北米のタンパク質工学市場展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • 製品タイプ別
  • 技術別
  • エンドユーザー別
  • 国別
• 北米：国別分析
  • 米国
  • メキシコ
  • カナダ

第9章 南米のタンパク質工学市場展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • 製品タイプ別
  • 技術別
  • エンドユーザー別
  • 国別
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカのタンパク質工学市場展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • 製品タイプ別
  • 技術別
  • エンドユーザー別
  • 国別
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 製品上市
• 合併と買収

第13章 世界のタンパク質工学市場のSWOT分析

第14章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第15章 PESTLE分析

第16章 競合情勢

• Agilent Technologies Inc.
• Amgen Inc.
• Bruker Corporation
• Bio-Rad Laboratories Inc.
• Eli Lilly and Company
• Merck KGaA
• Novo Nordisk AS
• PerkinElmer Inc.
• Thermo Fisher Scientific Inc.
• Waters Corporation
• Genscripts USA, Inc.
• GE Healthcare

第17章 戦略的提言

第18章 調査会社・免責事項

Global Protein Engineering Market has valued at USD 2.56 billion in 2022 and is anticipated to witness an impressive growth in the forecast period with a CAGR of 11% through 2028. Protein engineering is a branch of biotechnology that involves the deliberate design, modification, and optimization of proteins to create new functions, improve existing ones, or tailor them for specific applications. Proteins are essential biological macromolecules that perform a wide range of functions in living organisms, including catalyzing chemical reactions (enzymes), transporting molecules, providing structural support, and regulating cellular processes. Protein engineering harnesses the understanding of protein structure and function to manipulate these molecules for various purposes. Advances in molecular biology techniques have made it possible to synthesize and modify genes encoding proteins with specific sequences. This allows researchers to create entirely new proteins or modify existing ones for various applications.

The growing demand for biopharmaceuticals, including monoclonal antibodies, vaccines, and other protein-based therapies, was a significant driver. Protein engineering techniques are essential for optimizing the production and efficacy of these drugs. Ongoing advancements in genomics, transcriptomics, and proteomics were providing valuable insights into the role of proteins in disease pathways. This knowledge fueled the demand for protein engineering techniques to develop targeted therapies. The biotechnology and pharmaceutical industries were experiencing sustained growth, with increased investment in research and development. This growth was driving the demand for protein engineering tools and services. Protein engineering was playing a crucial role in the development of therapies for rare and orphan diseases. The potential for high returns in this niche market was a driver for investment and innovation. Protein engineering was being used to design enzymes with enhanced properties for various industrial applications, including biofuel production, food processing, and waste management.

Key Market Drivers

Technological Advancements

Technological advancements in protein engineering have played a pivotal role in shaping the field and expanding its applications in various industries, including pharmaceuticals, biotechnology, agriculture, and industrial processes. Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) and CRISPR-associated protein 9 (Cas9) technology revolutionized protein engineering. It allows precise genome editing, making it possible to modify genes and engineer proteins with high specificity and efficiency. This has far-reaching implications in drug development, agriculture, and basic research. Directed evolution is a powerful technique that mimics natural selection to optimize proteins for specific functions. Through iterative rounds of mutation and selection, researchers can engineer proteins with enhanced properties, such as increased affinity, stability, or enzymatic activity. High-Throughput Screening (HTS) methods have become more sophisticated and automated, enabling the rapid screening of large libraries of proteins for desired properties. This accelerates the discovery of novel enzymes, therapeutic antibodies, and other protein-based products. Advances in computational methods, including molecular modeling and machine learning, allow researchers to predict the structure and function of engineered proteins. This saves time and resources in the design phase and helps in understanding protein-ligand interactions. Synthetic biology techniques enable the creation of entirely new proteins and biological systems. Researchers can design and synthesize genes encoding novel proteins with tailored functions, expanding the possibilities for protein engineering. Improvements in protein expression systems, such as yeast, bacteria, and mammalian cells, have enhanced the production of recombinant proteins and therapeutic antibodies. These advancements increase the yield and quality of engineered proteins.

Understanding protein folding and stability is crucial for protein engineering. Computational tools and experimental techniques have improved the prediction of protein structures and stability, aiding in the design of more robust proteins. Next-Generation Sequencing (NGS) technologies have facilitated the analysis of genetic variation and expression patterns, allowing researchers to identify and characterize potential protein engineering targets more effectively. Cell-free protein synthesis systems have become more efficient and versatile. They enable the rapid production of proteins without the need for living cells, making it easier to engineer and study various proteins. Recent developments in genome editing technologies like CrispRGold and Prime Editing offer even greater precision and control in modifying genetic sequences. These advancements have far-reaching implications for gene therapy and protein engineering. Techniques such as ChIP-seq and protein-DNA cross-linking enable researchers to study protein-DNA interactions at the molecular level. This is critical for understanding gene regulation and designing DNA-binding proteins. Advancements in single-cell proteomics technologies allow the profiling of individual cells' protein content, providing insights into cellular heterogeneity and disease mechanisms. This factor will help in the development of the Global Protein Engineering Market.

Growing Biotechnology and Pharmaceutical Sectors

The biotechnology and pharmaceutical industries have witnessed a shift towards biologics, which are drugs derived from living organisms. This includes monoclonal antibodies, vaccines, and other protein-based therapeutics. Protein engineering plays a crucial role in designing, optimizing, and producing these biologics, meeting the increasing demand for more targeted and effective treatments. The process of discovering and developing new drugs often involves the identification and modification of specific proteins associated with diseases. Protein engineering techniques enable the modification of these proteins to enhance their therapeutic properties or to create entirely new drug candidates. The pharmaceutical sector is increasingly moving towards personalized medicine, where treatments are tailored to individual patient profiles. Protein engineering allows for the customization of therapeutic proteins to match the genetic and molecular characteristics of individual patients, improving treatment outcomes. Protein engineering has been instrumental in the development of therapies for rare and orphan diseases, which may not have large patient populations. The pharmaceutical industry has shown interest in these niche markets, driving demand for protein engineering services and technologies.

The biopharmaceutical industry relies on biomanufacturing processes to produce large quantities of protein-based drugs. Protein engineering helps optimize the expression, yield, and stability of these therapeutic proteins, ensuring efficient and cost-effective production. Pharmaceutical companies continuously seek to expand their drug pipelines with innovative and differentiated products. Protein engineering allows for the development of novel biologics and protein-based therapies, helping companies stay competitive. The development of combination therapies, where multiple drugs are used to target different aspects of a disease, is a growing trend in the pharmaceutical sector. Protein engineering can be employed to design complementary therapeutic proteins that work together synergistically. As patents for some biologic drugs expire, there is a growing market for biosimilars, which are highly similar versions of existing biologics. Protein engineering is used to create biosimilars with comparable efficacy and safety profiles. Biotechnology and pharmaceutical companies invest heavily in research and development to bring new drugs to market. This investment includes funding for protein engineering research and technology development. Collaboration between pharmaceutical companies, biotech firms, and academic institutions in protein engineering research has become common. These partnerships drive innovation and accelerate the development of protein-based therapies. Events like the COVID-19 pandemic have highlighted the need for rapid vaccine and therapeutic development. Protein engineering played a pivotal role in the development of COVID-19 vaccines and treatments, showcasing its importance in addressing global health challenges. This factor will pace up the demand of the Global Protein Engineering Market.

Increased Focus on Rare Diseases

Rare diseases, also known as orphan diseases, often lack effective treatments due to their low prevalence. Protein engineering offers a promising approach to develop tailored therapies for these diseases, addressing significant unmet medical needs. The study of rare diseases often involves identifying specific genetic mutations or protein abnormalities that underlie these conditions. Protein engineering allows for the customization of therapeutic proteins to precisely target the molecular pathways involved in rare diseases, enabling precision medicine approaches. Governments and regulatory agencies worldwide provide incentives for the development of orphan drugs to treat rare diseases. Protein engineering is instrumental in designing and optimizing these drugs, including monoclonal antibodies and enzyme replacement therapies. Rare diseases are often caused by specific protein abnormalities. Protein engineering techniques enable the development of targeted therapies that can correct or compensate for these abnormalities, leading to improved treatment outcomes.

Monoclonal antibodies engineered to target rare disease-related proteins have shown significant promise in treating conditions such as certain forms of muscular dystrophy and lysosomal storage disorders. Protein engineering is closely linked to gene therapy, which holds great potential for treating rare genetic disorders. Engineered proteins, such as viral vectors or enzymes, can be used to deliver therapeutic genes to patients with rare diseases. For certain rare metabolic disorders, enzyme replacement therapies are essential. Protein engineering techniques can optimize the stability, activity, and targeting of these therapeutic enzymes. The orphan drug market has been growing steadily, driven by a combination of regulatory incentives, increased funding, and advances in protein engineering technologies. This growth encourages investment in research and development for rare diseases. Collaboration between academic researchers, pharmaceutical companies, and patient advocacy groups in the field of rare diseases has become more common. Such collaborations accelerate research and the development of protein-based therapies. Strong advocacy efforts by patient groups and foundations dedicated to rare diseases have raised awareness and support for research and treatment development. These efforts drive funding and interest in protein engineering solutions. Advances in diagnostic technologies, such as genomics and proteomics, enable the identification of rare disease-specific biomarkers. Protein engineering can then be used to develop diagnostics and targeted therapies. This factor will accelerate the demand of the Global Protein Engineering Market.

Key Market Challenges

Complexity of Protein Design

Proteins have complex three-dimensional structures that are crucial for their functions. Designing proteins with specific structures that fold correctly is a challenging task, as small changes in amino acid sequences can lead to misfolding and loss of function.Predicting the exact function of a designed protein can be challenging. Many proteins have multifaceted roles within biological systems, and designing a protein to perform a specific function can be highly complex. Ensuring that a designed protein is stable and properly folds into its functional conformation is a significant challenge. Achieving the correct protein fold is crucial for its activity and efficacy. Proteins often interact with other molecules, such as ligands, cofactors, or other proteins. Designing a protein that interacts selectively and with high affinity with a particular molecule can be complex. Designing proteins that engage in specific protein-protein interactions can be particularly challenging. Predicting how different proteins will interact with one another and engineering those interactions accurately is complex. Protein design requires expertise in multiple disciplines, including biology, chemistry, bioinformatics, and structural biology. Collaborations among experts in these fields are often necessary.

Sustainability and Environmental Concerns

Protein engineering research often requires substantial resources, including laboratory equipment, consumables, and energy. The environmental impact of these resource-intensive processes can be a concern. The production of protein-based products, such as therapeutic proteins, enzymes, and alternative proteins (like plant-based and cell-based meats), can have environmental implications. Optimizing biomanufacturing processes to be more sustainable is a challenge. The development of genetically modified organisms (GMOs) for various applications, including agriculture and industrial biotechnology, raises environmental and regulatory concerns. Ensuring the safe use of GMOs and addressing potential ecological impacts is essential. Biomanufacturing processes can generate waste and byproducts that may have environmental consequences. Managing and minimizing waste streams is a sustainability challenge. Many protein engineering processes require controlled environments and precise conditions, which can be energy intensive. Reducing energy consumption and transitioning to renewable energy sources are priorities for sustainability. The use of chemicals in protein engineering, such as reagents for DNA synthesis and protein purification, can have environmental impacts. Developing greener chemistry approaches is a sustainability goal. While alternative proteins (plant-based and cell-based) are often considered more sustainable than traditional animal agriculture, their environmental footprint can vary. Reducing the environmental impact of these technologies is an ongoing challenge.

Key Market Trends

Expansion of Protein Engineering

Protein engineering is used to modify the genetic makeup of crops to enhance specific traits. This can include increasing resistance to pests and diseases, improving tolerance to environmental stressors (e.g., drought or salinity), and optimizing nutritional content. Developing crops with enhanced disease resistance through protein engineering reduces the need for chemical pesticides, contributing to environmentally friendly and sustainable agriculture. Engineering crops for pest resistance can protect yields and reduce the reliance on chemical insecticides, benefiting both the environment and farmers. Protein engineering can help create crops that are more resilient to drought conditions, which is critical in regions facing water scarcity and climate change challenges. Protein engineering is applied to increase the nutritional value of crops by enhancing the content of essential nutrients, such as vitamins and minerals. By improving crop yields and reducing the need for chemical inputs, protein-engineered crops can contribute to more sustainable and environmentally friendly agricultural practices. The use of genetically modified crops designed through protein engineering may lead to reduced soil erosion, lower greenhouse gas emissions, and decreased agricultural runoff, thus mitigating environmental harm. Biofortification involves increasing the levels of essential nutrients in crops. Protein engineering can play a role in biofortifying staple crops to address malnutrition and nutrient deficiencies in vulnerable populations.

Segmental Insights

Technology Insights

In 2022, the Global Protein Engineering Market rational protein design segment held the largest share and is predicted to continue expanding over the coming years. The technology's vast application in enzyme engineering and antibody development accounts for the dominant share. Enzyme engineering has seen a tremendous increase in its commercial uses, which has led to the creation of improved and modified enzymes with the appropriate catalytic capabilities. Site-directed mutagenesis is one method that is often employed in rational design engineering approaches, and its high market penetration helps to drive the category.

Product Type Insights

In 2022, the Global Protein Engineering Market monoclonal antibodies segment held the largest revenue share and is predicted to continue expanding over the coming years. The rising R&D expenditure for creating therapeutically improved monoclonal antibodies is one of the main factors influencing the increased utilisation of these technologies. Soon, the segment is anticipated to grow due to the rising use of targeted monoclonal antibodies for the treatment of cancer and other chronic diseases. Like this, the emergence of genetic platforms that employ cutting-edge technology, such as next-generation sequencing for enabling effective protein engineering for the development of monoclonal antibodies, is anticipated to significantly boost the growth potential.

End Use Insights

In 2022, the Global Protein Engineering Market pharmaceutical & biotechnology companies segment held the largest share and is predicted to continue expanding over the coming years. The significant portion is a result of the expanding usage of in silico drug research models for the treatment of neurological issues, cancer, and diabetes. These businesses constantly strive to preserve their market presence by using computer modelling to create drug versions of patent-expiring medications. The segment is also being driven by the increasing funding and financial support from public and commercial healthcare organisations for the creation of sophisticated protein engineering technologies that will improve patient outcomes.

Regional Insights

The North America region dominated the Global Protein Engineering Market in 2022. The bigger proportion that this region has grabbed is probably due to the increasing number of collaborations that major market participants have promoted for improving their R&D capabilities. The high market share has been influenced by the existence of important companies in the area, including Agilent Technologies and Thermo Fisher Scientific, Inc.

The Asia Pacific region is projected to grow at the fastest CAGR over the forecast period. Because developing Asian nations have high rates of autoimmune, cardiovascular, and cancer diseases. Additionally, the high economic development in emerging economies like India and China is anticipated to support the sector's expansion in this area's unexplored prospects. Additionally, it is projected that the region's expansion will be aided by the availability of a sizable population base for the research and clinical testing of protein engineering applications.

Key Market Players

• Agilent Technologies Inc.

• Amgen Inc.

• Bruker Corporation

• Bio-Rad Laboratories Inc.

• Eli Lilly and Company

• Merck KGaA

• Novo Nordisk AS

• PerkinElmer Inc.

• Thermo Fisher Scientific Inc.

• Waters Corporation

• Genscripts USA, Inc.

• GE Healthcare

Report Scope:

In this report, the Global Protein Engineering Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Protein Engineering Market, By Product Type:

• Insulin
• Monoclonal Antibodies
• Coagulation Factors (Blood Factors + Tissue Plasminogen)
• Vaccines
• Growth Factors (Hormones + Cytokine)
• Other Product Types

Protein Engineering Market, By Technology:

• Irrational Protein Design
• Rational Protein Design

Protein Engineering Market, By End User:

• Pharmaceutical and Biotechnology Companies
• Academic Institutions
• Contract Research Organizations (CROs)

Global Protein Engineering Market, By region:

• North America
• United States
• Canada
• Mexico
• Asia-Pacific
• China
• India
• South Korea
• Australia
• Japan
• Europe
• Germany
• France
• United Kingdom
• Spain
• Italy
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE

Competitive Landscape

• Company Profiles: Detailed analysis of the major companies present in the Global Protein Engineering Market.

Available Customizations:

• Global Protein Engineering Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Protein Engineering Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product Type (Insulin, Monoclonal Antibodies, Coagulation Factors (Blood Factors + Tissue Plasminogen), Vaccines, Growth Factors (Hormones + Cytokine), and Other Product Types)
  • 5.2.2. By Technology (Irrational Protein Design and Rational Protein Design)
  • 5.2.3. By End User (Pharmaceutical and Biotechnology Companies, Academic Institutions, and Contract Research Organizations (CROs))
  • 5.2.4. By Region
  • 5.2.5. By Company (2022)
• 5.3. Market Map

6. Asia Pacific Protein Engineering Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product Type
  • 6.2.2. By Technology
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. Asia Pacific: Country Analysis
  • 6.3.1. China Protein Engineering Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product Type
      • 6.3.1.2.2. By Technology
      • 6.3.1.2.3. By End User
  • 6.3.2. India Protein Engineering Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product Type
      • 6.3.2.2.2. By Technology
      • 6.3.2.2.3. By End User
  • 6.3.3. Australia Protein Engineering Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product Type
      • 6.3.3.2.2. By Technology
      • 6.3.3.2.3. By End User
  • 6.3.4. Japan Protein Engineering Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Product Type
      • 6.3.4.2.2. By Technology
      • 6.3.4.2.3. By End User
  • 6.3.5. South Korea Protein Engineering Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Product Type
      • 6.3.5.2.2. By Technology
      • 6.3.5.2.3. By End User

7. Europe Protein Engineering Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product Type
  • 7.2.2. By Technology
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Protein Engineering Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product Type
      • 7.3.1.2.2. By Technology
      • 7.3.1.2.3. By End User
  • 7.3.2. Germany Protein Engineering Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product Type
      • 7.3.2.2.2. By Technology
      • 7.3.2.2.3. By End User
  • 7.3.3. Spain Protein Engineering Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By Type
  • 7.3.4. Italy Protein Engineering Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product Type
      • 7.3.4.2.2. By Technology
      • 7.3.4.2.3. By End User
  • 7.3.5. United Kingdom Protein Engineering Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product Type
      • 7.3.5.2.2. By Technology
      • 7.3.5.2.3. By End User

8. North America Protein Engineering Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product Type
  • 8.2.2. By Technology
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. North America: Country Analysis
  • 8.3.1. United States Protein Engineering Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product Type
      • 8.3.1.2.2. By Technology
      • 8.3.1.2.3. By End User
  • 8.3.2. Mexico Protein Engineering Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product Type
      • 8.3.2.2.2. By Technology
      • 8.3.2.2.3. By End User
  • 8.3.3. Canada Protein Engineering Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product Type
      • 8.3.3.2.2. By Technology
      • 8.3.3.2.3. By End User

9. South America Protein Engineering Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product Type
  • 9.2.2. By Technology
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Protein Engineering Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product Type
      • 9.3.1.2.2. By Technology
      • 9.3.1.2.3. By End User
  • 9.3.2. Argentina Protein Engineering Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product Type
      • 9.3.2.2.2. By Technology
      • 9.3.2.2.3. By End User
  • 9.3.3. Colombia Protein Engineering Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product Type
      • 9.3.3.2.2. By Technology
      • 9.3.3.2.3. By End User

10. Middle East and Africa Protein Engineering Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product Type
  • 10.2.2. By Technology
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Protein Engineering Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product Type
      • 10.3.1.2.2. By Technology
      • 10.3.1.2.3. By End User
  • 10.3.2. Saudi Arabia Protein Engineering Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product Type
      • 10.3.2.2.2. By Technology
      • 10.3.2.2.3. By End User
  • 10.3.3. UAE Protein Engineering Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product Type
      • 10.3.3.2.2. By Technology
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global Protein Engineering Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Product

15. PESTLE Analysis

16. Competitive Landscape

• 16.1. Agilent Technologies Inc.
  • 16.1.1. Business Overview
  • 16.1.2. Company Snapshot
  • 16.1.3. Products & Services
  • 16.1.4. Financials (In case of listed companies)
  • 16.1.5. Recent Developments
  • 16.1.6. SWOT Analysis
• 16.2. Amgen Inc.
  • 16.2.1. Business Overview
  • 16.2.2. Company Snapshot
  • 16.2.3. Products & Services
  • 16.2.4. Financials (In case of listed companies)
  • 16.2.5. Recent Developments
  • 16.2.6. SWOT Analysis
• 16.3. Bruker Corporation
  • 16.3.1. Business Overview
  • 16.3.2. Company Snapshot
  • 16.3.3. Products & Services
  • 16.3.4. Financials (In case of listed companies)
  • 16.3.5. Recent Developments
  • 16.3.6. SWOT Analysis
• 16.4. Bio-Rad Laboratories Inc.
  • 16.4.1. Business Overview
  • 16.4.2. Company Snapshot
  • 16.4.3. Products & Services
  • 16.4.4. Financials (In case of listed companies)
  • 16.4.5. Recent Developments
  • 16.4.6. SWOT Analysis
• 16.5. Eli Lilly and Company
  • 16.5.1. Business Overview
  • 16.5.2. Company Snapshot
  • 16.5.3. Products & Services
  • 16.5.4. Financials (In case of listed companies)
  • 16.5.5. Recent Developments
  • 16.5.6. SWOT Analysis
• 16.6. Merck KGaA
  • 16.6.1. Business Overview
  • 16.6.2. Company Snapshot
  • 16.6.3. Products & Services
  • 16.6.4. Financials (In case of listed companies)
  • 16.6.5. Recent Developments
  • 16.6.6. SWOT Analysis
• 16.7. Novo Nordisk AS
  • 16.7.1. Business Overview
  • 16.7.2. Company Snapshot
  • 16.7.3. Products & Services
  • 16.7.4. Financials (In case of listed companies)
  • 16.7.5. Recent Developments
  • 16.7.6. SWOT Analysis
• 16.8. PerkinElmer Inc.
  • 16.8.1. Business Overview
  • 16.8.2. Company Snapshot
  • 16.8.3. Products & Services
  • 16.8.4. Financials (In case of listed companies)
  • 16.8.5. Recent Developments
  • 16.8.6. SWOT Analysis
• 16.9. Thermo Fisher Scientific Inc.
  • 16.9.1. Business Overview
  • 16.9.2. Company Snapshot
  • 16.9.3. Products & Services
  • 16.9.4. Financials (In case of listed companies)
  • 16.9.5. Recent Developments
  • 16.9.6. SWOT Analysis
• 16.10. Waters Corporation
  • 16.10.1. Business Overview
  • 16.10.2. Company Snapshot
  • 16.10.3. Products & Services
  • 16.10.4. Financials (In case of listed companies)
  • 16.10.5. Recent Developments
  • 16.10.6. SWOT Analysis
• 16.11. Genscripts USA, Inc.
  • 16.11.1. Business Overview
  • 16.11.2. Company Snapshot
  • 16.11.3. Products & Services
  • 16.11.4. Financials (In case of listed companies)
  • 16.11.5. Recent Developments
  • 16.11.6. SWOT Analysis
• 16.12. GE Healthcare
  • 16.12.1. Business Overview
  • 16.12.2. Company Snapshot
  • 16.12.3. Products & Services
  • 16.12.4. Financials (In case of listed companies)
  • 16.12.5. Recent Developments
  • 16.12.6. SWOT Analysis

17. Strategic Recommendations

18. About Us & Disclaimer